Powering our way to the elusive side effect: A composite outcome 'basket' of predefined designated endpoints in each organ system should be included in all controlled trials

Journal of Clinical Epidemiology

Volumn 58, Issue 8, 2005, Pages 785-790

  Tugwell, Peter ^a   Judd, Maria G ^a   Fries, Jim F ^b   Singh, Gurkirpal ^b   Wells, George A ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical trials; Composite endpoints; COX 2; Measurement; Outcome assessment; Responsiveness

Indexed keywords

ACETYLSALICYLIC ACID; BENOXAPROFEN; CELECOXIB; CERIVASTATIN; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETANERCEPT; IBUPROFEN; INDOMETACIN; INFLIXIMAB; MEFLOQUINE; MYCOPHENOLIC ACID; NAPROXEN; ROFECOXIB; THALIDOMIDE;

ABDOMINAL PAIN; ANXIETY; CLINICAL TRIAL; COUGHING; DEMENTIA; DEMYELINATING DISEASE; DEPRESSION; DIARRHEA; DIGESTIVE SYSTEM ULCER; GASTROINTESTINAL HEMORRHAGE; GOUT; HEART INFARCTION; HORMONE SUBSTITUTION; HUMAN; INFECTION; LIVER TOXICITY; LUPUS ERYTHEMATOSUS; MARKET; MENINGITIS; METHODOLOGY; MOOD DISORDER; MORBIDITY; MORTALITY; NAUSEA; OBSTRUCTION; OSTEOARTHRITIS; PHOCOMELIA; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SAFETY; SIDE EFFECT; SLEEP DISORDER; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; ULCER PERFORATION;

EID: 22044434417     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2004.11.028     Document Type: Article

References (36)

1. C. Bombardier, L. Laine, A. Reicin, D. Shapiro, R. Burgos-Vargas, B. Davis, R. Day, M.B. Ferraz, C.J. Hawkey, M.C. Hochberg, T.K. Kvien, T.J. Schnitzer, and VIGOR Study Group Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group N Engl J Med 343 2000 1520 1528 2 p following 1528
2. F.E. Silverstein, G. Faich, J.L. Goldstein, L.S. Simon, T. Pincus, A. Whelton, R. Makuch, G. Eisen, N.M. Agrawal, W.F. Stenson, A.M. Burr, W.W. Zhao, J.D. Kent, J.B. Lefkowith, K.M. Verburg, and G.S. Geis Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study JAMA 284 2000 1247 1255
3. J.E. Rossouw, G.L. Anderson, R.L. Prentice, A.Z. LaCroix, C. Kooperberg, M.L. Stefanick, R.D. Jackson, S.A. Beresford, B.V. Howard, K.C. Johnson, J.M. Kotchen, J. Ockene, and Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial JAMA 288 2002 321 333
4. A.M. Croft, and A. Herxheimer Adverse effects of the antimalaria drug, mefloquine: due to primary liver damage with secondary thyroid involvement? BMC Public Health 2 2002 6
5. P.J. Barrett, P.D. Emmins, P.D. Clarke, and D.J. Bradley Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers BMJ 313 1996 525 528
6. Baycol Information [Internet]. Updated August 8, 2001. Accessed June 4, 2003. Available at: http://www.fda.gov/cder/drug/infopage/baycol/default.htm.
7. U.S. Food and Drug Administration, Press Office. Bayer Voluntarily Withdraws Baycol [Internet]. Updated August 8, 2001. Accessed April 6, 2003. Available at: http://www.fda.gov/bbs/topics/ANSWERS/2001/ANS01095.html.
8. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Approval package for Baycol [Internet]. Updated June 26, 1997. Accessed June 4, 2003. Available at: www.fda.gov/cder/foi/nda97/ 020740ap_baycol_medrp1.pdf.
9. B.R. Allen, and D.A. Brewerton Lessons from benoxaprofen Lancet 2 8299 1982 667
10. R. Smith Medical journals and pharmaceutical companies: uneasy bedfellows BMJ 326 2003 1202 1205
11. Matthew T, Desmond P, Isaacs D, Lander C, Shenfield G, Wainwright D; Australian Drug Evaluation Committee; editors. Drugs that make you forget. Australian Adverse Drug Reactions Bulletin 1998;17(3):3 [Available at: http://www.tga.gov.au/docs/pdf/aadrbltn/aadr9808.pdf ].
12. Centocor. Important drug warning: Remicade (infliximab) [cover letter for product label] [Internet]. Updated October 5, 2001. Available at: http://www.fda.gov/medwatch/safety/2001/remicadeTB_deardoc.pdf.
13. Wyeth Ayerst, Immunex. Important drug warning: Enbrel (etanercept) [cover letter for product label] [Internet]. Updated October 10, 2000. Available at: http://www.fda.gov/medwatch/safety/2000/enbrel1.pdf.
14. U.S. Food and Drug Administration. Guidance documents [Internet]. Available at: http://www.fda.gov/cder/guidance/guidance.htm.
15. L.M. Friedman, C.D. Furberg, and D.L. DeMets Fundamentals of clinical trials 3rd ed. 1998 Springer-Verlag New York
16. P. Tugwell, and C. Bombardier A methodologic framework for developing and selecting endpoints in clinical trials J Rheumatol 9 1982 758 762
17. M. Boers, P. Brooks, V. Strand, and P. Tugwell The OMERACT filter for outcome measures in rheumatology J Rheumatol 25 1998 198 199
18. M. Boers, P. Tugwell, D.T. Felson, P.L.C.M. van Riel, J.R. Kirwan, J.P. Edmonds, J.S. Smolen, N. Khaltaev, and K.D. Muirden WHO and ILAR core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials J Rheumatol 21 Suppl 41 1994 86 89
19. M. Dougados, P. Leclaire, D. van der Heijde, D.A. Bloch, N. Bellamy, and R.D. Altman Response criteria for clinical trials on osteoarthritis of the knee and hip: a report of the Osteoarthritis Research Society International Standing Committee for Clinical Trials response criteria initiative Osteoarthritis Cartilage 8 2000 395 403
20. P. Brooks, M. Hochberg, ILAR, and OMERACT Outcome measures and classification criteria for the rheumatic diseases: a compilation of data from OMERACT (Outcome Measures for Arthritis Clinical Trials), ILAR (International League of Associations for Rheumatology), regional leagues and other groups Rheumatology (Oxford) 40 2001 896 906
21. J.F. Fries Toward an understanding of patient outcome measurement Arthritis Rheumatol 26 1983 697 704
22. G. Singh Gastrointestinal complications of prescription and over-the-counter nonsteroidal anti-inflammatory drugs: a view from the ARAMIS database. Arthritis, Rheumatism, and Aging Medical Information System Am J Ther 7 2000 115 121
23. G. Singh, and G. Triadafilopoulos Epidemiology of NSAID induced gastrointestinal complications J Rheumatol 26 Suppl 56 1999 18 24
24. T.G. Woodworth, D.E. Furst, V. Strand, J. Kempeni, H. Fenner, C.S. Lau, F. Miller, R. Day, J. Lipani, and P. Brooks Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT Toxicity Working Group March 2000: towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapies J Rheumatol 28 2001 1163 1169
25. Arthritis Singh G. Rheumatism and Aging Medical Information System Post-Marketing Surveillance Program [ARAMIS-PMS] J Rheumatol 28 2001 1174 1179
26. L.S. Simon, A.L. Weaver, D.Y. Graham, A.J. Kivitz, P.E. Lipsky, R.C. Hubbard, P.C. Isakson, K.M. Verburg, S.S. Yu, W.W. Zhao, and G.S. Geis Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial JAMA 282 1999 1921 1928
27. P. Tubert-Bitter, R. Manfredi, J. Lellouch, and B. Begaud Sample size calculations for risk equivalence testing in pharmacoepidemiology J Clin Epidemiol 2000 1268 1274 Dec:53
28. G. Wells, D. Beaton, B. Shea, M. Boers, L. Simon, V. Strand, P. Brooks, and P. Tugwell Minimal clinically important differences: review of methods J Rheumatol 28 2001 406 412
29. M. Boers NSAIDS and selective COX-2 inhibitors: competition between gastroprotection and cardioprotection Lancet 357 2001 1222 1223
30. J. Ioannidis, P. Chew, and J. Lau Standardized retrieval of side effects data for meta-analysis of safety outcomes: a feasibility study in acute sinusitis J Clin Epidemiol 55 2002 619 626
31. J.A. Sacristan, J.C. Gomez, X. Badia, and P. Kind Global index of safety (GIS): a new instrument to assess drug safety J Clin Epidemiol 54 2001 1120 1125
32. N.R. Cook, P.R. Hebert, J.E. Manson, J.E. Buring, and C.H. Hennekens Self-selected posttrial aspirin use and subsequent cardiovascular disease and mortality in the physicians' health study Arch Intern Med 160 2000 921 928
33. R.W. Beck, D.L. Chandler, S.R. Cole, J.H. Simon, L.D. Jacobs, R.P. Kinkel, J.B. Selhorst, J.W. Rose, J.A. Cooper, G. Rice, T.J. Murray, and A.W. Sandrock Interferon β-1a for early multiple sclerosis: CHAMPS trial subgroup analyses Ann Neurol 51 2002 481 490
34. M.L. Blute, D.G. Bostwick, T.M. Seay, S.K. Martin, J.M. Slezak, E.J. Bergstralh, and H. Zincke Pathologic classification of prostate carcinoma: the impact of margin status Cancer 82 1998 902 908
35. D.T. Felson, J.J. Anderson, M. Boers, C. Bombardier, M. Chernoff, B. Fried, D. Furst, C. Goldsmith, S. Kieszak, and R. Lightfoot The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials Arthritis Rheum 36 1993 729 740
36. C.P. Cannon, P.J. Sharis, M.J. Schweiger, C.H. McCabe, D.J. Diver, P.K. Shah, R.F. Sequeira, R.M. Greene, R.L. Perritt, W.K. Poole, and E. Braunwald Prospective validation of a composite endpoint in thrombolytic trials of acute myocardial infarction (TIMI 4 and 5). Thrombosis In Myocardial Infarction Am J Cardiol 80 1997 696 699